Tonix Pharmaceuticals announced that it has licensed technology related to oxytocin-based therapies for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from the French National Institute of Health and Medical Research (Inserm). According to Tonix, patents included in the license provide exclusivity through 2031 in the US and Europe.
The company is adding the TNX-2900 intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome to its pipeline alongside TNX-1900 oxytocin nasal spray for the treatment of migraine headaches, which was acquired from Trigemina in June 2020 and intranasal oxytocin for the treatment of insulin resistance and obesity, acquired from the University of Geneva in December 2020.
Tonix President and CEO Seth Lederman commented, “Prader-Willi syndrome is a rare genetic disorder of failure to thrive in infancy and uncontrolled appetite and obesity in childhood and adulthood with no approved treatments available. With the license from Inserm Transfert, we have the opportunity to expand our ongoing efforts with intranasal potentiated oxytocin to this new indication. Since Prader-Willi syndrome is an orphan disease that occurs in approximately one in 15,000 births, we plan at the appropriate time to submit an application to the US Food and Drug Administration for Orphan Drug and Fast Track designations for TNX-2900.”
Read the Tonix Pharmaceuticals press release.
